CABANA 试验:合并心衰的房颤患者导管消融与药物治疗比较
CABANA 试验随机纳入 2204 例房颤患者,其中 778 例(35%)基线 NYHA 心功能分级 >II 级构成此分析人群,分别接受导管消融或药物治疗。中位随访 48.5 个月,意向性分析显示消融组主要复合终点相对降低 36%(HR 0.64,95%CI 0.41-0.99),全因死亡相对降低 43%(HR 0.57,95%CI 0.33-0.96),房颤复发减少(HR 0.56,95%CI 0.42-0.74),生活质量改善。
要点
- 合并心衰的房颤患者,导管消融较药物降低主要复合终点 36%(HR 0.64,95%CI 0.41-0.99)。
- 全因死亡相对降低 43%(HR 0.57,95%CI 0.33-0.96),中位随访 48.5 个月。
- 房颤复发减少(HR 0.56,95%CI 0.42-0.74),生活质量评分改善。
核心结论
- 在 CABANA 试验入组时临床诊断为稳定性心衰的房颤患者中,导管消融较药物治疗在生存、房颤复发和生活方式方面产生临床重要改善。
- 这些结果大多来自左心室功能保留的患者,尚需独立试验验证。
研究设计与样本
- CABANA 试验将 2204 例年龄≥65 岁或<65 岁且≥1 项卒中危险因素的房颤患者随机分配至肺静脉隔离消融或药物( rate 或节律控制药物)治疗,共 126 个中心。
- 其中 778 例(35%)基线 NYHA 心功能分级 >II 级构成此分析人群,消融组 378 例,药物组 400 例。
- 主要终点为死亡、致残性卒中、严重出血或心脏骤停的复合终点,中位随访 48.5 个月。
主要发现
- 意向性分析中,消融组主要复合终点相对降低 36%(HR 0.64,95%CI 0.41-0.99)。
- 全因死亡相对降低 43%(HR 0.57,95%CI 0.33-0.96)。
- 房颤复发减少(HR 0.56,95%CI 0.42-0.74)。
- AFEQT 总结分在 60 个月随访期间平均调整均差为 5.0 分,倾向消融组(95%CI 2.5-7.4 分)。
- MAFSI 频率评分差异为 -2.0 分,倾向消融组(95%CI -2.9 至 -1.2)。
关键数值与推荐
- 基线射血分数数据 available 于 571 例(73.0%),其中 9.3% 射血分数 <40%,11.7% 射血分数在 40% 至 50% 之间。
临床怎么用
- 对于合并临床稳定性心衰的房颤患者,导管消融可能较药物治疗改善生存、减少房颤复发并提高生活质量。
- 需注意该分析人群大多左心室功能保留,结果需独立试验验证后再推广。
局限性
- 结果大多来自左心室功能保留的患者,需独立试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failure enrolled in the CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation). METHODS: The CABANA trial randomized 2204 patients with AF who were ≥65 years old or <65 years old with ≥1 risk factor for stroke at 126 sites to ablation with pulmonary vein isolation or drug therapy including rate or rhythm control drugs. Of these, 778 (35%) had New York Heart Association class >II at baseline and form the subject of this article. The CABANA trial's primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. RESULTS: Of the 778 patients with heart failure enrolled in CABANA, 378 were assigned to ablation and 400 to drug therapy. Ejection fraction at baseline was available for 571 patients (73.0%), and 9.3% of these had an ejection fraction <40%, whereas 11.7% had ejection fractions between 40% and 50%. In the intention-to-treat analysis, the ablation arm had a 36% relative reduction in the primary composite end point (hazard ratio, 0.64 [95% CI, 0.41-0.99]) and a 43% relative reduction in all-cause mortality (hazard ratio, 0.57 [95% CI, 0.33-0.96]) compared with drug therapy alone over a median follow-up of 48.5 months. AF recurrence was decreased with ablation (hazard ratio, 0.56 [95% CI, 0.42-0.74]). The adjusted mean difference for the AFEQT (Atrial Fibrillation Effect on Quality of Life) summary score averaged over the entire 60-month follow-up was 5.0 points, favoring the ablation arm (95% CI, 2.5-7.4 points), and the MAFSI (Mayo Atrial Fibrillation-Specific Symptom Inventory) frequency score difference was -2.0 points, favoring ablation (95% CI, -2.9 to -1.2). CONCLUSIONS: In patients with AF enrolled in the CABANA trial who had clinically diagnosed stable heart failure at trial entry, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life relative to drug therapy. These results, obtained in a cohort most of whom had preserved left ventricular function, require independent trial verification. Registration: URL: https://www.clinicaltrials.gov/ct2/show/NCT00911508; Unique identifier: NCT0091150.
引用
- Packer DL, Piccini JP, Monahan KH, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation. 2021. PMID: 33554614. doi:10.1161/CIRCULATIONAHA.120.050991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。